Trimethylangelicin as CFTR corrector in bronchial epithelial cells
AssigneesAzienda Ospedaliera Universitaria Integrata Di Verona, Universita' Degli Studi Di Ferrara, Universita' Degli Studi Di Bari, Rare Partners Srl
InventorsGiulio Cabrini, Valeria Casavola, Roberto Gambari
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of 4,6,4′-trimethylangelicin (TMA) and structural analogs thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508del-CFTR mutation.
Claims2
A method of correcting CFTR in patients suffering from cystic fibrosis and carrying mutation F508del-CFTR, either in heterozygous or homozygous state, said method comprising:
- administering an effective amount of a CFTR corrector to said patients suffering from cystic fibrosis and carrying said mutation F508del-CFTR either in heterozygous or homozygous state;
- and
- correcting said CFTR in said patients,
- wherein said CFTR corrector is trimethylangelicin.
Dependencies are inferred from the claim text.